BioWorld

Dec. 22, 2005

View Archived Issues

Genzyme Acquires Avigen's AAV Assets For $12M, More

Eight months after Avigen Inc. decided to stop funding its adeno-associated virus technology, it found a buyer in Genzyme Corp. (BioWorld Today) Read More

Oscient, FDA Agree On Phase III Plan For Antibiotic Ramoplanin

Read More

As One Large-Scale Project Begins, Another Called For

Read More

Acologix's Series C: $25M For AC-820 Phase III Trial

Read More

Other News to Note

Read More